Cerebrospinal fluid biomarkers of neurodegeneration in narcolepsy type 1

Research output: Contribution to journalArticlepeer-review


Study Objectives: To measure the levels of five neurodegenerative biomarkers in the cerebrospinal fluid (CSF) of patients with narcolepsy type 1 (NT1) with variable disease duration. Methods: Following a standardized protocol of CSF collection and storage, we measured CSF total- and phosphorylated-tau, amyloid-beta 1-40 and 1-42, and neurofilament light chain (NfL) proteins in 30 nonneurological controls and 36 subjects with NT1, including 14 patients with recent disease onset (i.e. ≤12 months, short disease duration group). Results: CSF levels of all biomarkers were similar in NT1 subjects and controls. The comparison between NT1 with short and long disease duration only revealed slightly higher levels of CSF amyloid-beta 1-40 in the former group (median 9,549.5, interquartile range [IQR] 7,064.2-11,525.0 vs. 6,870.0, IQR 5,133.7-9,951.2, p = 0.043). CSF storage time did not influence the levels of the tested biomarkers. Conclusions: The measurement of CSF total-tau, phosphorylated-tau, amyloid-beta 1-40 and 1-42, and NfL proteins is not informative in NT1.

Original languageEnglish
Article numberzsz215
Issue number2
Publication statusPublished - Feb 1 2020


  • amyloid
  • cerebrospinal fluid
  • hypersomnia
  • narcolepsy
  • neurodegenerative
  • neurofilament protein
  • sleepiness
  • tau

ASJC Scopus subject areas

  • Clinical Neurology
  • Physiology (medical)


Dive into the research topics of 'Cerebrospinal fluid biomarkers of neurodegeneration in narcolepsy type 1'. Together they form a unique fingerprint.

Cite this